Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Menarini Group
organization3 mentionslast seen Sep 29, 2026
Italy-based pharmaceutical and diagnostics company with commercialization rights for obicetrapib in Europe.
Relationships 4
Relationship
NewAmsterdam Pharma Company N.V.partners withMenarini Group
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGARSep 29, 2026NewAmsterdam Pharma Co N.V. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Commercialization rights of obicetrapib in Europe have been exclusively granted to the Menarini Group
- filingSEC EDGARSep 21, 2026NewAmsterdam Pharma Co N.V. 8-K: Item 8.01: Other Events
NewAmsterdam Pharma Company N.V. (the "Company") along with its partner Menarini Group ("Menarini") announced that the European Commission ("EC") has granted marketing authorization
- newsPR NewswireSep 21, 2026Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
NewAmsterdam and Menarini continue to advance the clinical development of obicetrapib